Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Ramucirumab in Progressive TCC
NCT04179110Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in transitional cell carcinoma (TCC), sponsored by Yale University. Planned start Sep 2020; status: withdrawn.
02
Drugs
ramucirumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NCT04179110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179110.